Hereditary Cancer Testing Market Report 2026

The hereditary cancer testing market size has grown rapidly in recent years. It will grow from $4.75 billion in 2025 to $5.3 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing awareness of hereditary cancer risks, availability of next-generation sequencing platforms, expansion of diagnostic laboratory networks, rising physician recommendation for genetic testing, growth of personalized risk assessment models.

The hereditary cancer testing market size is expected to see rapid growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to expansion of population-scale genetic screening, increasing use of ai-driven genomic analysis, growth in preventive oncology initiatives, rising demand for cost-effective testing solutions, enhanced regulatory support for genetic diagnostics. Major trends in the forecast period include increasing adoption of multi-gene panel testing, rising demand for early cancer risk detection, growing use of advanced genetic sequencing technologies, expansion of preventive testing programs, enhanced integration of clinical decision support tools.

The growing overall burden of cancer is expected to drive the growth of the hereditary cancer testing market in the coming years. Cancer comprises a group of diseases marked by uncontrolled and abnormal cell growth that can invade surrounding tissues and spread to other parts of the body. Under normal conditions, cell growth, division, and death occur in a regulated manner. Hereditary cancer testing plays a vital role in managing the rising cancer burden by identifying individuals who carry a genetic predisposition to certain types of cancer. By evaluating inherited genetic mutations and familial risk factors, this testing helps pinpoint high-risk individuals, enabling early intervention, tailored treatment approaches, and preventive strategies. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia increased from 160,570 in 2022 to 164,694 in 2023, indicating a significant year-on-year rise. This increase underscores the expanding prevalence of cancer and, in turn, supports the growth of the hereditary cancer testing market.

Companies operating in the hereditary cancer testing market are increasingly emphasizing advanced technologies, such as molecular diagnostic tumor testing, to improve diagnostic precision, enhance patient outcomes, and support personalized treatment planning. Molecular diagnostic tumor testing involves the examination of genetic and molecular features of tumors to guide therapeutic decisions and predict disease progression. For instance, in February 2023, Chubb Business Services India Private Limited, an India-based global insurance company, introduced Cancer Advocate Plus. This program incorporates genetics-based testing to identify inherited gene mutations associated with increased cancer risk. Such an approach enables individuals to better understand their cancer susceptibility, supporting early detection and the development of personalized care strategies.

In March 2024, Ambry Genetics, a US-based genetic testing company, entered into a collaboration with Tempus AI to provide integrated germline and somatic testing services. The partnership is designed to expand access to comprehensive genomic information, improve the accuracy of cancer diagnostics, and facilitate personalized treatment strategies, while also fostering innovation and growth within the molecular diagnostics sector. Tempus AI is a US-based precision medicine company that leverages advanced data and technology to accelerate personalized healthcare and optimize patient outcomes.

Major companies operating in the hereditary cancer testing market are Centogene NV, Ambry Genetics Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, PreventionGenetics, Fulgent Genetics Inc., Invitae Corporation, Medical Diagnostic Laboratories LLC, Natera Inc., Color Health Inc., CooperSurgical Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes Ltd., Associated Regional and University Pathologists Inc., 4baseCare, Biocartis Group NV, F. Hoffmann-La Roche AG, Medgenome Pvt. Ltd., Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies PLC, PerkinElmer Inc.

North America was the largest region in the hereditary cancer testing market in 2025. The regions covered in the hereditary cancer testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary cancer testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hereditary cancer testing market by increasing costs of imported sequencing instruments, reagents, consumables, and bioinformatics hardware. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported genetic testing platforms, while Asia-Pacific faces higher costs for laboratory equipment procurement. These tariffs are increasing test pricing and affecting accessibility for patients. However, they are also encouraging local manufacturing of diagnostic reagents, regional sequencing infrastructure development, and domestic innovation in genetic testing technologies.

The hereditary cancer testing market research report is one of a series of new reports that provides hereditary cancer testing market statistics, including hereditary cancer testing industry global market size, regional shares, competitors with a hereditary cancer testing market share, detailed hereditary cancer testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary cancer testing industry. This hereditary cancer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hereditary cancer testing refers to diagnostic methods used to identify inherited cancer conditions and associated gene mutations linked to hereditary cancers. This testing can help reduce the risk of developing certain cancers by enabling a more comprehensive assessment of an individual’s cancer susceptibility. The primary objective of hereditary cancer testing is the early identification of cancer risk, thereby supporting timely intervention and improved patient health outcomes. The testing process aids in recognizing cancers for which an individual has a genetic predisposition and enables the adoption of preventive or risk-reducing treatment strategies.

The main categories of hereditary cancer tests include multi-panel tests and single-site genetic tests. Multi-panel testing involves analyzing multiple genes or markers at the same time. These panels vary in size, ranging from tests that examine three targets to those assessing five, seven, or even twelve targets, with the selection of panel size determined by the clinician or testing specialist. Hereditary cancer testing is commonly performed to identify risks associated with breast cancer, ovarian cancer, colorectal cancer, and other conditions, and is carried out in hospitals, clinics, and diagnostic centers.

The hereditary cancer testing market includes revenues earned by entities by providing hereditary cancer testing for lung cancer, cervical cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, and uterine cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.